Semaglutide
Ozempic, Rybelsus, Wegovy
A long-acting GLP-1 receptor agonist used for type 2 diabetes and obesity management by enhancing insulin secretion and suppressing appetite.
Completed
PHASE1
NCT06716307
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2, PHASE3
NCT06423599
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
Jens D Hove, MD,PHD
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2, PHASE3
NCT06387199
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
McGill University Health Centre/Research Institute of the McGill University Health Centre
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06497049
Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and OzempicĀ®.
Geropharm
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT05891496
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06097390
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NA
NCT05333003
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
Centre for Addiction and Mental Health
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05015894
A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06260722
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NCT06790160
Study of Patients Being Treated With Anti-obesity Medication
Texas Tech University
OBSERVATIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NCT07251803
GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound
Medical University of South Carolina
OBSERVATIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06221969
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06374875
Fibrosis Lessens After Metabolic Surgery
Ali Aminian
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NCT06761703
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
Amgen
OBSERVATIONAL
Updated Dec 15, 2025
Active Not Recruiting
NCT05756764
Anti-obesity Pharmacotherapy and Inflammation
Louisiana State University Health Sciences Center in New Orleans
OBSERVATIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NCT07229170
Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients
San Raffaele Telematic University
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT07202247
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Enrolling By Invitation
NCT07179796
Digital Physical Activity Program
Sword Health, SA
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06132477
Impact GLP-1 Agonists Following Bariatric
University of Missouri-Columbia
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE4
NCT04892199
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
Anders Fink-Jensen, MD, DMSci
INTERVENTIONAL
Updated Dec 15, 2025